Novartis (NVS) Stock Forecast & Price Target

$116.65

+0.16 (+0.14%)

(As of 09/6/2024 ET)

Novartis - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce
Based on 7 Analyst Ratings

Based on 7 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 7 analysts, 1 has given a sell rating, and 6 have given a hold rating for NVS.

Consensus Price Target

$118.38
1.48% Upside

High Forecast	$122.50
Average Forecast	$118.38
Low Forecast	$114.00

According to the 7 analysts' twelve-month price targets for Novartis, the average price target is $118.38. The highest price target for NVS is $122.50, while the lowest price target for NVS is $114.00. The average price target represents a forecasted upside of 1.48% from the current price of $116.65.

Type	Current Forecast 9/9/23 to 9/8/24	1 Month Ago 8/10/23 to 8/9/24	3 Months Ago 6/11/23 to 6/10/24	1 Year Ago 9/9/22 to 9/9/23
Consensus Rating	Reduce	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	2 Buy rating(s)	1 Buy rating(s)	3 Buy rating(s)
Hold	6 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$118.38	$118.13	$116.67	$85.00
Forecasted Upside	1.48% Upside	14.74% Upside	14.59% Upside	-4.45% Downside

Get Novartis Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Ad Paradigm Press

Fmr CIA Advisor reveals PEACEMAKER superweapon

Kamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.

Full details are in this announcement.

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novartis Stock vs. The Competition

Type	Novartis	Medical Companies	S&P 500
Consensus Rating Score	1.86	2.77	2.51
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	1.48% Upside	1,206.55% Upside	11.36% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/5/2024	The Goldman Sachs Group 2 of 5 stars	J. Quigley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$119.00 ➝ $121.00	+1.37%
9/3/2024	Jefferies Financial Group 2 of 5 stars		Downgrade	Buy ➝ Hold
7/19/2024	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Reiterated Rating	Buy ➝ Hold
6/24/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
4/24/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$114.00 ➝ $116.00	+18.89%
1/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$114.00	+5.09%
Get the Latest News and Ratings for NVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.
12/18/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
4/19/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$75.00 ➝ $85.00	-13.28%
1/26/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
1/3/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Neutral
12/14/2022	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	CHF 82 ➝ CHF 84
12/5/2022	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
9/29/2022	Oddo Bhf Subscribe to MarketBeat All Access for the recommendation accuracy rating	Martial Descoutures Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	CHF 88
9/15/2022	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Dominic Lunn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform
9/14/2022	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 01:42 AM ET.

NVS Forecast - Frequently Asked Questions

What is Novartis' forecast for 2024?: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $118.38, with a high forecast of $122.50 and a low forecast of $114.00.
Should I buy or sell Novartis stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There is currently 1 sell rating and 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" NVS shares.
Does Novartis's stock price have much upside?: According to analysts, Novartis's stock has a predicted upside of 9.43% based on their 12-month stock forecasts.
Has Novartis been upgraded or downgraded by Wall Street analysts recently?: Over the previous 90 days, Novartis's stock had 1 upgrade and 1 downgrade by analysts.
What analysts cover Novartis?: Novartis has been rated by research analysts at Barclays, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, and The Goldman Sachs Group in the past 90 days.
Do Wall Street analysts like Novartis more than its competitors?: Analysts like Novartis less than other "medical" companies. The consensus rating for Novartis is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NVS compares to other companies.